1. Home
  2.  » 
  3. Events
  4.  » Then and Now – Delivering a Successful Therapeutic to Patients
Then and Now – Delivering a Successful Therapeutic to Patients

Date: Thursday, 20th May 2021​
Time: 2 p.m. CEST | 8 a.m. EDT

 

In today’s whirlwind of diagnostics, vaccines and therapeutics, we take a step back and look at how the world of development and manufacturing of biologics has evolved over the last 25 years, bringing together EuropaBio Members and 25th Anniversary Sponsor, Catalent.
We look back at changing experience from the last quarter of a century in the pathway to patients, plus how the latest advanced technologies translate into effective pre-clinical and clinical development and manufacturing. Hear expert presentations from EuropaBio Members and Catalent Biologics, before a detailed Q&A session with the audience on all aspects of developing a successful biologic in 2021.

Aspects to be discussed include:

  • What trends are driving growth in the pharma industry, and how are next generation therapies addressing previously unmet needs?
  • As advanced technologies travel through the pipeline, how are pharma companies, CDMOs and other partners able meet their complex and novel requirements?
  • In a global world, how do you embrace and integrate skills and capacity from multiple sites, often in different continents?
  • As complex, advanced medicines become reality, how do you work with regulators from the earliest stages of pre-clinical development to enable a smooth pathway to clinic and market?

FEATURED SPEAKER

 


Behzad Mahdavi, Ph.D.​, MBA

Vice President of Open Innovation, Biologics, Cell and Gene Therapy

With over 20 years’ experience in developing and implementing impactful growth strategies in the biopharmaceutical industries, Dr. Mahdavi joined Catalent in 2020 after a 13-year career at Lonza, where he held the role of Vice President Strategic Innovation & Alliances, and various board-level positions at other innovative companies. Prior to joining Lonza, he was Chief Executive Officer of SAM Electron Technologies, a venture capital-backed company in the life sciences field. He holds a doctorate in chemistry from the University of Sherbrooke, Canada, and also has a master’s in business administration from the University of Quebec in Montreal.

 

Tine Lewi, Ph.D.
Scientific Director, Janssen R&D/Clinical Innovation

Dr. Lewi is leading Patient Data For Research initiatives within Janssen Clinical Innovation, introducing novel projects in the area of data science. She has worked for several years in data management and analytics solution development and engages in RWD initiatives to optimise clinical research across the R&D lifecycle. Dr. Lewi has a special interest in using health data for early diagnosis and disease interception, understanding disease trajectories and treatment optimization through RWD. She has a background in medical informatics and applied economics and obtained a doctorate on patient insights and health communication for disease prevention.